Trials / Terminated
TerminatedNCT05039710
A Study of JNJ-75220795 in Japanese Participants
A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795 in Japanese Participants
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of single subcutaneous (SC) dose of JNJ-75220795 in Japanese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-75220795 | JNJ-75220795 will be administered as SC injection. |
| OTHER | Placebo | Matching placebo will be administered as SC injection. |
Timeline
- Start date
- 2021-11-08
- Primary completion
- 2023-02-17
- Completion
- 2023-02-17
- First posted
- 2021-09-09
- Last updated
- 2025-08-15
Locations
4 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05039710. Inclusion in this directory is not an endorsement.